TERT and glioblastoma: TERT promoter mutations have been previously identified in glioblastoma (84%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%) (33).